recombinant adenovirus-p53 SCH-58500

BIOLOGICAL3 trials

Sponsors

Merck Sharp & Dohme LLC, National Cancer Institute (NCI)

Conditions

Brain and Central Nervous System TumorsFallopian Tube CancerMetastatic CancerOvarian CancerPrimary Peritoneal Cavity Cancer

Phase 1

Gene Therapy in Treating Patients With Recurrent or Progressive Brain Tumors

CompletedNCT00004080

National Cancer Institute (NCI)Brain and Central Nervous System Tumors

Start: 1999-12-31Updated: 2009-02-09

SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)

CompletedNCT00002960

Merck Sharp & Dohme LLCFallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer +1

Start: 1999-06-30End: 2000-07-31Updated: 2016-02-04

Phase 2

Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer

TerminatedNCT00003880

Merck Sharp & Dohme LLCOvarian Cancer, Primary Peritoneal Cavity Cancer

Start: 1999-02-28End: 2001-08-31Updated: 2015-04-16